Usefulness of thromboelastography in predicting hypercoagulability in patients undergoing free tissue transfer by Chien, Diana
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2018
Usefulness of thromboelastography
in predicting hypercoagulability in




   
BOSTON UNIVERSITY 
 












USEFULNESS OF THROMBOELASTOGRAPHY IN PREDICTING 
HYPERCOAGULABILITY IN PATIENTS UNDERGOING MICROSURGICAL 
















Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2018  






































© 2018 by 
 DIANA CHIEN 
 All rights reserved  






First Reader   
 C. James McKnight, Ph.D. 
 Associate Professor of Physiology and Biophysics 
 
 
Second Reader   
 Dhruv Singhal, M.D. 
 Director of Lymphatic Surgery 
 Assistant Professor of Surgery  








 I would like to thank Dr. Nathan White and Dr. Alex St. John for helping spark 
my initial interest in both medicine and thrombosis and hemostasis related research. I 
would also like to thank Dr. Dhruv Singhal, Dr. Bao Ngoc Tran, and Anna Rose Johnson 
for their support and guidance while working on this project. A special thanks to Dr. 
Singhal for allowing me to lead my own project and giving me the opportunity to gain 
insight into the field of plastic and reconstructive surgery. Furthermore, thank you to Dr. 
Adam Lerner, for allowing me to use your TEG machines and re-training me on how to 
















USEFULNESS OF THROMBOELASTOGRAPHY IN PREDICTING 
HYPERCOAGULABILITY IN PATIENTS UNDERGOING MICROVASCULAR 
FREE TISSUE TRANSFER 
DIANA CHIEN 
ABSTRACT 
 Reconstructive microvascular surgery is performed on over 5 million patients in the 
United States each year. Important sub-populations are patients with breast cancer and 
trauma to their lower extremities, which affects over 120,000 patients. While data has 
demonstrated that the failure rates for these free tissue transfers as a result of vascular clot 
formation is limited, there lacks a mechanism to predict the chances of such failures. Such 
complications increase hospital length of stay and health care costs. The aim of the study 
was to demonstrate the efficacy of using Thromboelastography (TEG) as a point-of-care 
test in order to identify hypercoagulable patients, monitor coagulability changes over the 
course of free flap reconstruction, and ultimately use this data to predict post-operative 
microvascular compromise. Following IRB approval, we attempted to recruit both lower 
extremity trauma patients (N=5) and patients with active breast cancer (N=5) undergoing 
free flap reconstruction. Blood was collected pre-operatively and intra-operatively, at the 
time of anastomosis. Standard and Heparinase TEG were performed on each sample within 
2 hours of collection. We were unable to recruit patients from the trauma population but 
did identify 5 breast cancer patients. Hypercoagulability was defined as having low R and 
high α-angle values (p = 0.04 and 0.02, respectively), in the presence or absence of high 
MA and low R-values. Based on this definition, 80% of patients were found to become 
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hypercoagulable over the course of the surgical procedure. While no patients experienced 
post-operative microvascular complications. As a result, we discovered that TEG has the 
ability to identify hypercoagulability and that over the course of a free flap reconstruction, 
breast cancer patients are likely to become more hypercoagulable when compared to 
baseline values. Following the recruitment of more patients, TEG could potentially be a 
useful supplemental tool in microvascular surgery in order to monitor coagulability 
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Coagulation and Hemostasis 
 
Hemostasis is a complex biological process that is dependent upon the interaction 
of platelets, cytokines, the coagulation cascade, various proteins, and vascular 
endothelium. Its end goal is to halt hemorrhage and continue normal circulation past the 
site of vascular injury. Upon vascular injury, our body’s hemostatic mechanism kicks in 
and works to seal off the impairment and limits its interaction from surrounding tissues. 
(Periayah et al., 2017). The entire process of hemostasis can be broken up into 3 main 
components: vasoconstriction, primary hemostasis, and secondary hemostasis.  
Our blood vessels’ first response to injury is vascular spasm. This response is 
triggered by a multitude of factors including damaged smooth muscle, chemicals released 
by exposed endothelial cells, and our innate reflexes. The result of such vasoconstriction 
slows and reduces the flow of blood through the damaged vessels, thereby limiting overall 
blood loss. Following this step, the damaged subendothelial matrix releases a glycoprotein 
called von Willebrand factor (vWf), which acts as a binder of exposed collagen and 
platelets. Once platelets bind to collagen, they become activated and release ADP. This 
release of ADP ultimately attracts more platelets, leading to the generation of a platelet 
plug at the site of vascular injury. This generation of a platelet plug is also known as 
primary hemostasis. Under normal conditions, platelets freely flow and do not aggregate 
in vessels. In order to prevent inappropriate platelet aggregation, the endothelium also 
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releases nitrous oxide (NO) and prostacyclin’s at uninjured sites to prevent this from 
occurring (Gale et al., 2011).  
While this platelet plug is forming, secondary hemostasis has already begun to 
occur. When damage to the endothelium occurs, blood becomes exposed to extravascular 
tissue that is rich in a protein known as Tissue Factor (TF). This interaction ultimately 
results in the activation and propagation of the extrinsic pathway of the coagulation 
cascade.  
The coagulation cascade is divided into two pathways: intrinsic and extrinsic, 
converging on the activation of Factor X. The extrinsic pathway is often considered to be 
the first step in hemostasis that is mediated by plasma components (Lasne et al., 2006). 
When trauma occurs, Factor VII is converted into Factor VIIa, it’s active form. TF 
additionally becomes exposed rom subendothelial tissue. Under normal conditions, there 
is limited interaction between TF and procoagulant factors in order to minimize thrombus 
formation. However, this exposed TF, as a direct result of trauma, binds Factor VIIa and 
Calcium together and allows for the activation of Factor Xa (Owens et al., 2011). On the 
other hand, the intrinsic pathway occurs from the activation of Factor XII into Factor XIIa. 
This then results in the activation of Factor XIa, which then activated Factor IXa. This then 
works along with Factor VIII (cofactor) to form a complex on a phospholipid surface that 
results in the activation of Factor Xa (Esmon, 2014). Following the activation of Factor V 
and Factor X, platelet phospholipids, calcium, and tissue phospholipids work to form a 
prothrombinase complex that is able to convert prothrombin into its active form, thrombin, 
as shown in Figure 1.  Thrombin then works by cleaving soluble fibrinogen into insoluble 
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fibrin that forms a mesh, or network, over the platelet plug and works to reinforce it. This 
process, known as secondary hemostasis, occurs simultaneous to platelet plug formation 






Figure 1. Coagulation Cascade. Hemostasis is a complex pathway that results in the 
activation of the coagulation cascade. Activation can occur through the intrinsic or extrinsic 
mechanism. Both pathways ultimately converge on FX. When FX is activated into FXa, it 
can then cleave prothrombin into its active form, thrombin. Thrombin is required for the 
final steps of clot formation, fibrin activation and cross-linking. This cross-linked fibrin is 
then further stabilized by activated FXIIa. At the same time that the coagulation cascade is 
being activated, so is the fibrinolytic system, but at a slower rate. This is an important 
mechanism in the regulation of hemostasis. During this time, plasminogen is converted 
into its active form, plasmin which results in the degradation of fibrin. Image adapted from 
Loof et al., 2014.  
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Although the coagulation cascade and clot formation are crucial steps during wound 
healing, and is welcomed by surgeons in the operating room, problems start to arise when 
excessive clotting results in venous thromboembolisms (VTE). 
VTE is the second most common medical complication in the U.S., resulting in 
prolonged length of stays and increased healthcare costs (Fernandez et al., 2015). As the 
population ages and increases in size, the incidence of this disease is also on the rise. 
Furthermore, surgical procedures involving trauma, cancer, obesity, lower extremities, and 
prolonged immobilization are the most common perioperative risk factors for VTE 
(Frederick et al., 2003). 
VTE includes both pulmonary embolism (PE) and deep vein thrombosis (DVT) and 
is often a complication of both surgery and trauma (Gary et al., 2016). In the United States 
alone, VTE occurs with an incidence of 1 per 1,000 adults annually (Cushman et al., 2007). 
Major risk factors for these thrombotic events includes age, gender, pre-existing 
hypercoagulation disorders, and cancer. Patients who required hospitalization as a result of 
cancer have a 5% chance of VTE whereas those who present due to trauma have a 6% 
chance, most likely due to the rarity of this event (Cushman et al., 2004). However, there 
is reason to believe that the true incidence of VTE is significantly higher than recorded 
because this disease often goes undiagnosed and untreated. Therefore, a complete 
understanding and identification of associated risk factors is necessary in order to minimize 
morbidity and mortality, due to thrombosis, in such high-risk patients – particularly breast 




Breast cancer, trauma, and thrombosis. How do they relate? 
 
Cancer has long been recognized as an independent risk factor for VTE and is 
associated with a 4.1-fold increase in thrombosis risk and is the second leading cause of 
death in this patient population (Khalil et. al, 2015; Chew et. al, 2006). Furthermore, the 
variable use of screening techniques accounts for the large proportion of cases that go 
undetected (Kashuk 2009). Evidence has shown that certain cancers are more 
prothrombotic than others depending n stage and overall therapeutic intervention. 
Furthermore, those undergoing chemotherapy and surgery were considered the most at risk. 
In a study done by Rickles and Levine, it was discovered that 5-10% of cancer patients 
receiving chemotherapy had an increased incidence of VTE and increased to 15% if their 
cancer was metastatic (Rickels 1998). With this in mind, it was discovered that cancer 
patients are hypercoagulable at baseline. 
Several factors can be attributed to the prothrombotic state of cancer patients, 
including a wide array of tumor cell specific properties. Cancerous cells have the ability to 
interact with the coagulation system in numerous ways but are often grouped into 2 
categories: 1) the production and release of procoagulant factors, inflammatory cytokines, 
and fibrinolysis; and 2) interaction with other endothelial and blood components.  
The procoagulant nature of malignant cells allow them to cause fibrin deposition at sites of 
extravasation in the vasculature and in the tumor microenvironment. The most important 
of them being cancer procoagulant (CP) and TF.  
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CP is a cysteine protease (68kDa) produced by tumor cells. CP works by activating 
factor X by cleaving it at heavy chains different from those of the intrinsic or extrinsic 
mechanism (Gordon et al., 1991). This protein has only been detected in malignant tumor 
cells and not in normal cells. The CP antigen has further been shown to be higher in 85% 
of cancer patients as shown by enzyme linked immunosorbent assay (ELISA). Therefore, 
the link between procoagulant cancer activity (PCA) and CP has been thoroughly 
established (Edwards et al., 1993).  
TF is a transmembrane glycoprotein (47 kDa) that complexes with factor VII/VIIa 
and proteolytically activated factor IX and factor X. The TF described here is the same 
procoagulant that is always found in normal cells, the endothelium, and activated 
macrophages. However, under normal healthy conditions, TF is not expressed. It is only 
produced in response to inflammatory stimuli by cytokines – Interleukin (IL-1β), tissue 
necrosis factor (TNF), IL-8 and bacterial endotoxins. These pro-inflammatory cytokines 
are produced by activated macrophages and are also responsible for pathological pain 
(Zhang et al., 2007). However, unlike normal cells, TF is constitutively expressed and does 
not require activation by these pro-inflammatory stimulators.  
Fibrinolysis on the other hand is caused by the upregulation of proteins responsible 
for the fibrinolytic pathway that are expressed on tumor cell surfaces. They are made up of 
tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI1), and 
urokinase-type (uPA). Tumor cells have been shown to express high levels of both uPA 
and uPA receptors (uPAR) and can therefore facilitate fibrinolysis (Kolev et al., 2016). 
This receptor mediated relationship has also been shown to be responsible for hemorrhagic 
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events experienced by leukemia patients. Furthermore, these fibrinolytic factors are also 
involved in tumor progression, invasion, and metastasis. All of which influence the 
prothrombotic nature of cancer patients (Caine et al., 2002).  
Tumor cells are additionally responsible for the secretion of various pro-
inflammatory cytokines. IL-1β is activated as a result of inflammasome activation and 
cleavage of pro-IL-1β by capsase. Following activation, it, along with TNF-α, is capable 
of upregulating the expression of TF by vascular endothelial cells, and downregulating 
thrombin receptor, thrombomodulin (TM). This process ultimately results in the reduced 
activation of the protein C system, the main anticoagulant defense system, and the 
generation of a prothrombotic endothelium that ultimately results in patients having a 
hypercoagulable state. Cancerous cells can also interact with the endothelium indirectly, 
through pro-inflammatory cytokines, or directly. These direct mechanisms are due to cell-
cell adhesion to the vascular endothelium or extracellular matrix (ECM). The attachment 
of these cells to the endothelium promotes local activation of thrombosis through the 
release of cytokines that subsequently recruit leukocytes and platelets. This increased 
platelet activation results in higher rates of platelet turnover and decreased survival time 
(Henrickson et al.,1999). Furthermore, platelet activation is also due to the generation of 
cathepsin B like cysteine proteinase and ADP from cancer cells that results in elevated 
levels of vWf (Nierodzik et al., 1995).  This platelet aggregating ability of tumor cells, 
along with plasminogen activation, can also contribute to its metastatic potential.  
Furthermore, these cells additionally have the ability to activate macrophages that 
results in the induction of TF. Macrophages circulate the bloodstream and can congregate 
 
8 
to surfaces in response to inflammatory signals such as cytokines or immune complexes. 
However, under normal resting conditions they do not express TF (Delgiudice & White, 
2009). But, when they encounter tumor cells, macrophages will begin to express TF. These 
tumor-associated macrophages have also been linked to the activation of the hemostatic 
system and fibrin formation that occurs in tumor tissues (Caine et al.,2002). Thus, the 
activation of TF by tumor cells supports the clotting activation that is a direct result of 
cancerous tissues. This type of interaction that has been described between a cancer 
patient’s hemostatic system and tumor cells, is the ultimate cause of their pro-thrombotic 
state (Campello et al.,2018). 
Breast cancer is of particular interest because it is the most common malignancy in 
women, and compared to other malignancies, has a lower incidence of VTE. However, the 
risk of VTE increase 4-6-fold when their cancer has metastasized, are at advanced stages, 
or when patients are currently undergoing chemotherapy (Fennerty 2006). Therefore, it is 
important to have a clear understanding of each individual patient’s coagulation status.  
Similar to cancer, acute trauma has also been recognized as a risk factor for VTE 
events, with an estimated 12% of all cases being due to trauma (Park et al., 2016). Trauma, 
especially those involving orthopedic extremity injuries, has been shown to result in 
hypercoagulable states that are complicated by, not only VTE, but disseminated 
intravascular coagulation (DIC) that results in early coagulopathy, acute respiratory 
distress syndrome (ARDS), and systemic inflammatory response syndrome (SIRS) (Gando 
et al., 2004). All of which contribute to a high morbidity and mortality rate in this patient 
population (Selby et al., 2009). It has already been well established that following trauma, 
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TF and thrombin generation increase, and anticoagulants produced by the body, including 
protein C, protein S, and antithrombin, are reduced (Meissner et al., 2003). Together with 
the activation of both the complement system and coagulation cascade, these variables are 
responsible for the observed hypercoagulability in this patient population.  
Following any traumatic injury, the coagulation cascade is rapidly activated in 
order to induce hemostasis and prevent bacterial infection, resulting in an inflammatory 
response leading to sepsis. As a result, the coagulation system is often described as a part 
of our innate immunity due to its complement activation (Heirholzer & Billiar, 2001). 
Large volume blood loss and tissue trauma result in the activation of C3a and C5a, 
anaphylatoxins that act as potent mediators of inflammation. The generation of these 
fragments can have detrimental effects. Under normal conditions, these serine proteases 
can be activated by three pathways, as depicted in figure 2 – classical, alternative, or 
mannose-binding lectin. The classical pathway beings with the cleavage of C4 and C2 by 
C1 into the C4bC2a complex that results in the activation of C3 convertase. Additional 
binding by C3b also results in the activation of C5 convertase. C3 convertase then acts to 
cleave C3 into its active forms C3b and C3a. Whereas C5 convertase works to cleave C5 
into its active form, C5a. The mannose-binding lectin pathway differs only from the 
classical pathway in that it bypasses the need for activation of C4 and C2 by C1, and instead 
uses the mannose associated serine protease to directly activate C4 and C2 to make 
C4bC2a. The alternative pathway on the other hand, relies on the use of C3, factor B, and 
factor D in order to cleave off C3b and Bb in order to generate C3 convertase (Amara et 
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al., 2009). Together, these factors result in increased mast cell histamine release, 
degranulation, and macrophage recruitment leading to an inflammatory response.   
 
 
Figure 2. Complement Cascade. Visual representation of the 3 different pathways that 
can lead to complement activation – classical, lectin, and alternative. All 3 start with 
different activators, but ultimately converging with the formation of the C3 convertase 
enzyme. The end results in the formation of activated C3a and C5a that results in an 
inflammatory response. Image adapted from Borza et al., 2016. 
 
 
However, it has been discovered that following trauma, thrombin has the ability to 
act as a potent C5 convertase and generate high levels of C5a, in the absence of C3. 
Thrombin also has the ability to generate C3a in a dose-dependent nature and can result in 
the induction of more than a three-fold mast cell response. Researchers further discovered 
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that plasmin, the strongest serine protease, also has the ability to cleave both C3 and C5. 
Furthermore, tPA, a potent fibrinolytic, has been found to cause a C5a induced switch in 
mast cells resulting in a pro-thrombotic state (Wojta et al., 2004). As a result, this change 
in the balance between the fibrinolytic and coagulation state, along with changes in the 
inflammatory response, play a crucial role in increasing the incidence of hemorrhagic 
shock, sepsis, and hypercoagulability following trauma.  
This post-traumatic hypercoagulability is also due to elevated levels of fibrin and 
tissue factor that occurs as a direct result of trauma. This ultimately results in a 
dysregulation of thrombin production that makes these patients at such high risk of VTE.   
At baseline, both patient populations are considered to be pro-thrombotic and at a 
high risk of VTE. Because both breast cancer and lower extremity trauma patients, in 
particular, will likely undergo some type of microsurgical intervention or reconstruction, 
it is important to have a full understand of their coagulation status and monitor any 
hemostatic changes that occur throughout the procedure. Not only to increase survival rate, 





Over the last several decades, with improved techniques in microvascular surgery, 
free tissue transfer as a means of reconstruction has become increasingly popular with low 
failure rates. As the early identification and diagnosis of breast cancer has increased, so 
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have available treatment and reconstructive options. Plastic surgeons aim to provide 
patients with the best reconstructive options with the lowest morbidity rate. As a result, the 
deep inferior epigastric perforator (DIEP) flap has risen in popularity and become the gold 
standard at many institutions.  
Prior to the development of the DIEP flap, surgeons relied on the transverse rectus 
abdominis myocutaneous (TRAM) flap for breast reconstructions. Despite its numerous 
advantages, there remained significant complication rates due to donor site morbidity 
(Schusterman et al., 1992). Pedicle and free TRAM flaps involve the use of the entire rectus 
abdominis muscle and often leaves patients with reduced abdominal wall competence. 
Therefore, the use of a perforator flap for autologous breast reconstruction was established 
in order to provide patients with a safer and reproducible reconstruction and was first 
popularized by Allen and Treece in 1994 as an alternative to the TRAM flap (Hamdi et. al, 
2006). Unlike the TRAM flap, free DIEP flaps require only the use of skin and 
subcutaneous fat from the lower abdomen. Using this technique, the rectus abdominis 
remains untouched, thereby preserving abdominal wall function (Hamdi et al., 1999).  The 
soft consistency of abdominal tissue is what makes it a good candidate for autologous 
breast reconstruction by giving it a soft, natural look.  
Surgical panning of the DIEP flap first involves evaluation of the skin of the lower 
abdomen. Use of a doppler or abdominal CT provides detailed information on the size, 
location, and flow of perforator vessels (Heitmann et al., 2000). Proposed skin islands can 
then be easily marked over the center of identifiable perforators. Operatively, surgeons 
begin my making a fasciotomy on one side and intramuscular dissection is performed. 
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When the deep inferior epigastric artery and veins are dissected to, the are clipped in order 
to make the flap ischemic. Once the flap is weighed, it is ready for transfer to the breast. 
There, a venous and arterial anastomosis are made between the deep inferiors and the 
internal mammary vessel. Once clamps are removed, surgeons wait for flow through the 
artery and vein. The flap is then inspected for venous congestion, which has a reported 
incidence of 2-8% (Hamdi et al., 2006; Wechselberger et. al, 2001; Blondeel et. al, 2000).  
On the other hand, lower extremity traumas requiring free flap reconstructions 
require the use of different types of flaps. When deciding which flap is best suited for the 
patient and the injury, surgeons look at how cellularity, immunological properties, and 
vascularity work to impact fracture and wound healing. Because of the limited donor sites 
in these types of patients, flap location and tissue type must be chosen wisely. Studies have 
shown that muscle flaps have a higher rate of rapid wound and fracture healing, when 
compared to fasciocutaneous flaps. Muscle flaps are densely vascularized and their 
capillary networks are able to facilitate antimicrobial deposition, while eliminating dead 
space (Klebuc & Menn, 2013). Furthermore, they are able to overcome bacterial 
colonization, resulting in infections, more easily than skin or fasciocutaneous flaps.  They 
have also been proven to help promote bone repair with the help of osteogenic 
mesenchymal stem cells and cytokines such as fibroblast growth factor 2 and interleukin 6 
(Sabino et al., 2016). Regardless, fasciocutaneous flaps are still widely used. Therefore, it 
is important for surgeons to decide which flap is best suited for each individual patient.  
Flap failure is typically identifiable within the first 24 hours during the post-
operative period. It can occur due to microvascular compromise, despite meticulous 
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techniques from surgeons, and most often results in venous thrombosis (Novakovic et al., 
2009). In many cases, these unpredictable flap failures are caused by unknown patient 
related factors, including undiagnosed hypercoagulability (Sezgin, 2016). In cancer 
patients in particular, this effect is a direct result of several factors. It can be due to 
malignant tumor cell expression of CP which has the ability to directly bypass both the 
extrinsic and intrinsic pathway and activate factor X (Prandoni et al., 1996). Or, increased 
levels of TNF, IL-1,8, TF or vascular endothelial growth factor (VEGF) (Rickles et al., 
2001). All of these variables are ultimately associated with tumor related thrombotic 
events. Furthermore, tumors have the ability to downregulate our intrinsic anti-thrombotic 
proteins including thrombomodulin and tPA (Parker et al., 2012). Therefore, early 
identification of failing flaps is paramount to increasing success rates, thereby decreasing 




Thromboelastography (TEG) was first developed by German scientist, Dr. Hertert, 
in 1948, but was not put into clinical use well until late 1973. As a dual lane point-of-care 
test, it provides a real time viscoelastic assessment of clot strength in whole blood (Whiting 
& DiNardo, 2014). It functions by placing whole blood in a cup that is warmed at 37°C. 
Depending on the sample type, calcium is additionally added in order to activate clot 
formation. Once added, a pin is loaded into the cup and the cup is continuously rotated at 
4°25’, and the pin is connected to a torsion wire that relays data back to an electrical-
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mechanical transducer. As blood begins to clot and degrade within the cup, the change in 
the degree of torque is measured by the gauge (Figure 3). From there, this data is translated 
into measurable values that are plotted through signal translation, in real time (Kreitzer et 






Figure 3. TEG Cup and Pin Apparatus. Blood and other components are loaded into the 
cup. As the cup rotates, clot formation begins and the developing fibrin strands link the 
motion felt within the cup, to the pin. This is directly proportional to clot strength. As the 
overall degree of torque changes, it is detected by the torsion wire. This data is then sent to 
the electromechanical transducer, which then translates it into measurable values that are 
plotted into a graph. Image adapted from Kreitzer et al., 2015.  
 
This tool provides a visual assessment of clot formation and lysis in shear 
conditions similar to those in the vena cava and allows for the monitoring of a patients 
overall hemostatic function. The generated profile is a measure of the speed of clot 
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formation and dissolution. Because of its ability to monitor shear elasticity, the test is 
sensitive to all the cellular components in blood that may affect the rate or overall structure 
of the sample, as it is actively clotting, and its lysis. The final profile can then be used to 
identify whether a patient’s coagulation system is normal, hypocoagulable, or 
hypercoagulable, and the overall degree of lysis. It’s ability to identify which blood 
components are responsible for each phase of clot formation, allows for any irregularities 
in each part of the TEG tracing to serve a diagnostic purpose (Plotkin et al., 2008) 
 
 
Figure 4. TEG® 500 Hemostasis Analyzer. Cups are loaded into the white holder, and 
pins are loaded onto the top lever. Blood is then placed within the cups, along with any 
reagents. Once loaded, the cups are lifted up with the white base into the pins, and the level 
is moved to the right into the TEST position to begin the assay. Each machine has two 




The graphical output displayed from TEG, as shown in figure 5, is used to measure 
multiple parameters of clot formation and degradation through specific variables: R, K, α 
angle, MA, G, CI, LY30. R-time (R) represents the start of the test to the initial strand of 
fibrin formation, when the clot has reached an amplitude of 2mm. This is analogous to 
standard clotting studies. Elevated R values could indicate the need for fresh frozen plasma 
transfusions. K-time (K) represents the time it takes to achieve a certain level of clot 
strength. Using R as the starting time point, a K value is generated when an amplitude of 
20mm is reached. Elevated K values can therefore indicate the need for cryoprecipitate, a 
blood product containing fibrinogen, vWf, fibronectin, Factor XII and Factor VIII. Angle 
(α) represents the rate of clot growth. It is a direct measure of the rate at which fibrin 
accumulation and cross-linking occurs. A reduced angle could indicate the need for 
cryoprecipitate and/or platelet transfusions. Maximum amplitude (MA) represents the 
maximum strength (maximum shear modulus) of the developed clot, this is directly related 
to the strength of the clot. It is a direct measure of the relationship between fibrin and 
platelet function – 20% fibrinogen and 80% platelets. G measures the absolute clot 
firmness. Coagulation index (CI) describes the patient’s overall coagulation. Lysis at 30 
(LY30) represents the total fibrinolysis present 30 minutes after the maximum amplitude 
is reached. It acts as the earliest predictor of abnormal fibrinolytic states. Patients who are 
factor deficient and suffer from conditions such as thrombocytopenia or 
hypofibrinogenemia can be identified by TEG values. They generally present with long R 
and K, and reduced MA and α angles. (Thakur et al., 2012). The usefulness of TEG in the 
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early identification of factor, platelet, or fibrin deficiencies is crucial in reducing patient 
mortality and transfusion needs, making it more useful than standard coagulation testing. 
 
 
Figure 5.  Schematic Diagram of TEG Trace. As blood begins to clot in the presence of 
activators, viscoelastic changes are recorded by TEG, analyzed by a computer, and 
translated into this graphical representation. The values and graph generated by TEG are 
real-time interpretations of a patients overall hemostatic function. This image shows the 
relationship between the clotting cascade and TEG tracing. Any irregularities can be used 
for the early identification of deficiencies, coagulopathies, and transfusion requirements. 
For example, the R time is representative of the intrinsic pathway and directly measures 
clotting factors. Whereas the MA is a direct measure of platelet function and number. 






Unfractionated heparin is a naturally occurring anticoagulant that is most 
commonly used in patients who are at risk of DVT, PE, and arterial occlusions. In patients 
who have a history of heparin induced thrombosis or thrombocytopenia, the use of heparin 
is contraindicated (Zmuda et. al, 2000). Therefore, the use of heparinoids, a 
glycosaminoglycan derivative of heparin, is used to inhibit clot formation. Low molecular 
weight heparins (LMWH) are a commonly used type of heparinoid that includes 
enoxaparin sodium (Lovenox) – often used in patients undergoing cardiac bypass surgery, 
as well as trauma patients. As a result, patients who have received either unfractionated 
heparin or LMWH have abnormal coagulation assays on Standard TEGs.  
However, the addition of heparinase to TEG cups has the ability to reverse the 
effects of anticoagulant traces in blood samples from both heparin and enoxaparin sodium 
(lovenox), both commonly used in breast cancer and trauma populations. Both drugs have 
the ability to inhibit clot formation and weaken overall clot strength. Therefore, performing 
heparinase TEGs allows for the rule-out of heparin associated coagulation changes, such 
as hemorrhage or thrombolysis.  
 
Usefulness of TEG in trauma and microvascular surgery 
 
Standard coagulation assays including fibrinogen, platelet count, prothrombin time/ 
international normalized ratio (PT/INR), and activated partial thromboplastin time (aPTT) 
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are commonly used to identify factor deficiencies. However, these tests require the addition 
of buffers which makes them poor assays for the dynamic assessment of clot strength in 
whole blood samples. Furthermore, they only serve primarily as a measure of time until 
clot initiation (Spiess et al., 1995). Yet, they are still commonly used in clinical settings. 
TEG on the other hand has the ability to provide a comprehensive evaluation of the 
viscoelastic properties of blood and is often used in trauma resuscitations, obstetrics, 
intensive care units (ICU), liver transplants, and cardiac surgery (Kashuk et al., 2009). 
When trauma patients first arrive in the emergency department, they are most at 
risk for post-traumatic coagulopathy. This acts as the first predictor of future blood 
transfusions and mortality rates, as they have been found to have greater than a 50% chance 
of developing some type of thrombotic event (Schreiber et al., 2005). Therefore, their 
hemostatic function and status, on arrival, becomes the strongest indicator of outcome 
(Kaufmann et al., 1997). PT and PTT are commonly employed assays for these patients 
but are performed on platelet poor plasma samples. As a result, they do not provide 
information on the important interactions that occur between platelets and clotting factors 
and are unable to provide early identification of clotting deficiencies (Plotkin et al., 2008). 
TEG values on the other hand serve a diagnostic purpose and are able to guide transfusion 
requirements for drugs and fluids and identify factor or clotting deficiencies. For example, 
patients may present with normal TEG readings but have unstable, abnormal vital signs 
and could be suffering from internal bleeding that requires surgical intervention. In cases 
such as this, these TEG values could be used to guide transfusion requirements and reduce 
the overall need for them (Schreiber et al., 2005). 
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Aside from its usefulness in guiding transfusions, TEG has long been used for the 
early identification of coagulopathies and hypercoagulability in surgical patients and 
predict post-operative thrombotic events. More recently, the usefulness of TEG in 
microvascular surgery has been analyzed. In a recent study conducted by Parker et. al, the 
functional fibrinogen to platelet ratio was calculated from TEG tracings. They were then 
able to relate elevated ratios >42% to increased chances of patients developing some type 
of thrombotic event following free flap reconstruction during head and neck surgery 
(Parker et al., 2012). In another study by Zavlin et al. (2017), researchers were able to use 
TEG in order to identify hypercoagulable breast cancer patients undergoing free flap 
reconstructions. Using elevated G-values, they too were able to relate this to post-operative 
thrombotic events. However, despite its potential usefulness in predicting post-operative 
thrombotic complications, there lacks a general consensus on what TEG variables can be 
used to define hypercoagulability.  
 
Specific Aims and Goals 
 
Reconstructive microvascular surgery is performed on over 5 million patients in the 
United States each year. Important sub-populations are patients undergoing microsurgical 
breast reconstruction due to malignancy or microsurgery due trauma to their lower 
extremities, which affects over 120,000 individuals. These groups of patients are of interest 
because they are more prone to hypercoagulable states prior to surgery as a result of trauma, 
severity of injury, gender, underlying medical conditions, socioeconomic factors, past 
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medical history, current medications and much more. While data has demonstrated that the 
failure rates for these free tissue transfers as a result of vascular clot formation is limited, 
there lacks a mechanism to predict the chances of such failures. Such complications 
increase hospital length of stay, recovery time, and health care costs.  
The goal of this research is to determine the feasibility and efficacy of using TEG as a 
point-of-care test to identify hypercoagulable patients and predict post-operative 
thromboembolic complications. Specifically, TEG will be performed pre-operatively and 
intra-operatively on microsurgical breast reconstruction (N=5) and lower extremity trauma 
(N=5) patients. This preliminary data will be analyzed to determine if TEG may be a useful 
indicator of not only coagulation changes in a peri-operative setting, but if it may be a 
useful determinant for prophylactic anticoagulant needs in these patients. Specifically, this 
project aims to achieve the following: 
1) Obtain preliminary data on the feasibility of using TEG as a screening tool for 
hypercoagulability in microsurgical patients undergoing autologous breast 
reconstruction or those with lower extremity traumas. 
2) Define hypercoagulability in these patient populations using TEG variables   
3) Determine if such hypercoagulability may be a good predictor of thromboembolic 
complications in these patient populations. 
4) Identify coagulation changes that may occur as a direct result of microsurgical 
repair/ reconstruction  
a. Compare any similarities and differences in TEG tracings between these 




The goal of the present study was to examine the hypothesis that in these given 
patient populations, TEG will identify hypercoagulability and be able to predict 
thromboembolic complications. We further hypothesize that this change in coagulability is 
related to the patients’ underlying condition and may aid in determining the need for 








Following approval from the Institutional Review Board: Committee on Clinical 
Investigations (IRB CCI) at Beth Israel Deaconess Medical Center (BIDMC), medical 
records were analyzed for all patients with active malignancy scheduled to undergo 
autologous free flap breast reconstruction. Five patients undergoing uni- or bilateral 
mastectomy with immediate DIEP flap reconstruction were identified and recruited. All 
patients were pre-screened with a defined inclusion and exclusion criteria. These criteria 
allowed for the recruitment of women with active, malignant breast cancer over the age of 
18 who had no underlying known hematological disorders, were not currently taking anti-
coagulants, received no greater than 5,000 Units of Sub-Q Heparin 8 hours prior to surgery, 
were not currently pregnant, and underwent immediate free flap repair. All patients were 
approached in pre-operative holding on the day of their scheduled procedure where signed 
consent was obtained. Patient demographics, MRN, co-morbidities, procedural 
information – delays, complications, and TEG values were all stored in a secured REDCap 
Database accessible only to the study team. 
 
Sample Collection 
A total of 2 citrated whole-blood samples were collected from each patient: pre-
operative and intra-operative. From the time blood entered the syringe to the time it was 
placed in the TEG instrument, was between 20 minutes and 2 hours. Samples were not run 
outside of these times as they can affect TEG results.  
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Pre-operative blood draw: 
At the time of the placement of an indwelling non-heparinized catheter by 
anesthesia staff as standard of care, a total of 6 mL of blood was drawn for study 
purposes. The first 2-3mL, which contains tissue factor or line contaminants, was 
discarded. The last 3mL was transferred into a blue-capped tube containing 0.5mL 
of 3.2% (0.105 M) sodium citrate (pH 7.4). The tube was capped and blood was 
mixed with the citrated by gentle inversion 3 times in order to mix well, but not 
activate clotting factors. Patient labels with two identifiers were then placed on the 
tube and walked to the TEG analyzer.  
 
Intra-operative blood draw: 
Intra-operatively, at the time of anastomosis, a venipuncture using a 21-
Gauge winged collection needle, was performed on the lower extremity. A clean 
plastic syringe was then attached and 3mL of blood was drawn and wasted. A 
second syringe was then attached and another 3mL of blood was drawn. Following 
the same protocol as the pre-operative collection, the second 3mL was then 
transferred into a blue-capped tube containing 0.5mL of 3.2% (0.105 M) sodium 
citrate (pH 7.4). The tube was capped and blood was mixed with the citrated by 
gentle inversion 3 times in order to mix well, but not activate clotting factors. 
Patient labels with two identifiers were then placed on the tube and walked to the 
TEG analyzer.  




TEG® analysis was completed using the TEG® 5000 Hemostasis analyzer by 
Haemoscope (Haemoscope Corp, Niles, IL). The Thromboelastography® (TEG®) System 
consists of the TEG® Hemostasis Analyzer along with the TEG® Analytical Software. 
TEG® automatically records the visco-elastic changes in a sample of whole blood to 
generate a hemostatic profile. TEG® is a dual lane machine that contains a rotating sensor 
shaft/pin that is suspended in a small whole blood sample that oscillates back and forth. 
The signal is then transmitted by an optical detector and recorded by the system. As blood 
begins to clot in the cup, the change in speed of the rotation is translated into a graphical 
display that is a direct measure of the changes in shear elasticity of the developing clot.  
A disposable cup and pin (Haemoscope Corp, Niles, IL) are first loaded into the 
machine, that warms it at 37°C.  1mL of citrated whole blood is transferred from the blue 
top tube into a premeasured vial of Kaolin (Haemoscope Corp, Niles, IL) stored at 2°-8°C 
until use. The vial is then capped and inverted 5 times. 340μL of the Kaolin activated whole 
blood sample and 20μL of 0.2M Calcium Chloride (Haemoscope, Niles, IL), which is also 
stored at 2°-8°C until use, is added into the warmed cup. The cup is then loaded into the 
pin, the lever is moved to the TEST position, and the Standard TEG® analysis has begun. 
In order to negate the effects of any residual heparin in blood samples, Heparinase TEG® 
was also performed on each blood sample. Heparinase TEG® follows the same protocol 
as Standard TEG® but instead includes the used of disposable Heparianse I cups and pins 
(Haemoscope Corp, Niles, IL) that are stored at 2°- 8°C in a sealed plastic bag. Both 
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samples were run until LY30 was generated. Each patient had a total of 4 TEG® analyses 
performed on their blood samples.  
A complete set of TEG® biological controls was performed every 8 hours. Controls 
are stored at 2°-8°C and must be reconstituted in order to be activated. Two controls, Level 
I and Level II (Haemoscope Corporation, Niles, IL – Cataolig No. 8001 and 8002, 
respectively), are lyophilized in vials that must be reconstituted with distilled water, pre-
measured and included in boxes. The vial is shaken vigorously and must sit at room 
temperature for 5 minutes. The vial is then shaken again and allowed to sit for another 5 
minutes in order to allow for adequate rehydration. 20μL of 0.2M Calcium Chloride is then 
pipetted into each TEG® cup, along with 340μL of the reconstituted control, into the first 
lane. The cup is then raised upwards along the column, and the lever is moved into the test 
position. Controls must be run until the MA has been generated.  
TEG® values differ regionally, and therefore controls were obtained when TEG® 
500 was first acquired by the Departments of Pathology, Anesthesia, and Surgery at 
BIDMC. The reference range for citrated whole blood was performed by obtaining blood 
samples from 21 healthy volunteers. Samples were obtained by venipuncture. Using data 
from these 21 volunteers, manufacturer reference ranges were validated for parameters R, 
K, Angle, MA, and G. No manufacturer rangers were available for LY30 or CI, so BIDMC 
data was analyzed using a robust statistical method. Normal values were then generated for 
citrated whole blood samples as follows: 
 R = 5-10min 
 K = 1-3min 
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 Angle = 53°-72° 
 MA = 50-70mm 
 G = 4.5-11.0Kd/sc 
 CI = -6.2 to +0.2  
 
Statistical analysis 
Descriptive statistics were given by single factors. Statistical analysis was 
performed utilizing Microsoft Excel 2016 for Windows (Microsoft Corporation). For 
comparison between physiological and hypercoagulable groups, student’s t-test was used. 







A total of 5 patients with active breast cancer undergoing immediate microvascular 
free flap reconstruction were recruited, of which 100% were female. Mean age at the time 
of surgical intervention was 48.8 ± 11.62.  
20% of patients had a history of smoking, hypertension, and cardiac history. 
However, these variables were not significantly different between these 2 groups. No 
patients had a prior history of thromboembolic events or complications. All patients elected 
for immediate free flap reconstruction following a unilateral (80%) or bilateral (20%) 
mastectomy due to active malignancy (100%). The age distribution between patients with 
physiological and pathological TEGs did not significantly differ.  Furthermore, all patients 
underwent immediate DIEP flap reconstruction using abdominal fat and tissue (Table 1). 
In 2 patients (40%), pre-operative TEG was deemed hypercoagulable, whereas the 
remaining 3 patients had values that were within normal range. In all but 2 patients, pre-
operative blood was collected prior to the administration of 5,000U of Sub-Q Heparin, 
resulting in no identifiable heparin effect in their blood sample. As a result, the heparinase 
and standard TEG values from these patients were all within normal limits and within 1 
standard deviation of each other. 
 In 3 patients (60%), a heparin effect was identifiable from direct comparison 
between pre-operative heparinase and standard TEG values. These patients had their blood 
sampled following the administration of sub-Q heparin. All had noticeably lower R-values, 
when compared to normal limits, as a result of residual heparin. In addition, standard TEG 
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α-angle, MA, G, and CI values were lower than those from pre-operative heparinase TEG. 
(Figure 4a-b) 
Intra-operatively, 4 patients (80%) had different standard and heparinase TEG 
values as a direct result of heparin. Furthermore, of the 2 patients that presented with 
pathological TEGs pre-operatively, both continued to be hypercoagulable at the time of 
anastomosis. However, of the 3 patients that presented with physiological TEGs, pre-
operatively, 2 became hypercoagulable intraoperatively with reduced R and elevated α-
angle values. (Figure 4b). Mean R, K, and α-angle values were statistically different 
between physiological and pathological TEGs, whereas MA values were not (Table 2). 
In addition, of the 5 subjects, only 1 patient underwent bilateral skin sparing 
mastectomies. As a result, anastomosis did not occur until 8 hours into the procedure, 
whereas in all unilateral mastectomy cases, anastomosis occurred on average 5 hours into 
the procedure. In this patient, R and K times were prolonged, whereas α-angle, MA, G, CI, 
and LY30 were all reduced when compared to pre-operative TEG values.  
Overall, no patients experienced any form of microvascular compromise during the 











Table 1. Demographics. Comparison of patient demographics and past medical history  








Table 2. TEG Values. Average R, K, α-angle, and MA values for physiological and 



























R (min) 5.24 4.40 0.04 
K (min) 1.40 0.94 0.03 
α-angle (deg) 69.3 75.6 0.02 





Figure 6. Hypercoagulable vs. Normal TEG. Graphical TEG assays performed pre-
operatively from the same blood sample. (a) Heparinase TEG - represents 
hypercoagulability as seen from the shortened R and K times, and elevated α-angle and 
MA, when compared to both normal limits and standard TEG. Differences are also a result 
of heparin effect when compared to standard TEG sample. (b) Standard TEG – visible 












TEG was first described in the mid 1900’s but was not put into clinical use until 
years later. This was mainly due to the complex nature of not only the machine itself, but 
also the level of error associated with user variability. TEG is a highly sensitive assay, and 
as a result minute errors can lead to the generation of different coagulation profiles from 
the same blood sample. In recent years, TEG has been modified to reduce user related 
errors and generate more accurate coagulation profiles. For the purposes of this study, there 
were not multiple individuals performing TEG assays. Despite such variability, TEG has 
been long described as a highly useful point-of-care whole blood coagulation test that is 
capable of early identification of coagulopathies, reduce transfusion requirements, identify 
specific coagulation deficiencies, and much more. As a result, it’s use has slowly become 
integrated in cardiac ad hepatic surgeries, post-partum hemorrhage monitoring in 
obstetrics, and guiding trauma resuscitations. However, few studies have assessed the 
usefulness of such a powerful machine in microvascular surgery.  
Limited data exists on the use of TEG in monitoring peri-operative changes in 
breast cancer patients undergoing free flap reconstructions. In a recent study, Kolbenschlag 
et al. (2014) examined the use of rotational thromboelastometry, a point-of-care test similar 
in function to TEG, in identifying hypercoagulable states in all patients undergoing various 
types of microvascular free tissue transfer at their hospital. They then used this to predict 
thrombotic complications in these patients. They ultimately discovered that elevated 
extrinsic or intrinsic mean clot firmness values, as generated from rotational 
thromboelastometry, was indicative of hypercoagulability and could therefore be used to 
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identify patients at risk of developing thrombotic complications. Based on this conclusion, 
we became interested in seeing if the same could be said for TEG in the early identification 
of patients at risk of flap loss due to microvascular compromise. 
Early identification of thrombosis following microsurgical free tissue transfer, 
followed by rapid or immediate surgical or anticoagulant intervention is imperative to 
prevent flap loss (Mehrara et al., 2006). In many cases not involving free flap surgery, 
conventional coagulation testing is insufficient, and the ability to predict bleeding and 
thrombotic events is highly limited. Peri-operatively, these patients experience micro- and 
macrovascular changes that directly impacts their peri- and post-operative outcomes. 
Therefore, monitoring any changes in coagulability peri-operatively is important 
immediately prior to the establishment of anastomosis in these small vessels.  
For this study, we decided to perform TEG assays both pre- and intra-operatively 
in order to define hypercoagulability and determine if, and any, changes in coagulability 
occurred between these two timepoints.  
Based on TEG values, hypercoagulability was defined as having low R and high α-
angle values, in the presence or absence of high MA and low K values. Pre-operatively, of 
the 5 patients recruited for this study, we found that 3 had hypercoagulable heparinase 
TEGs, either pre- or intra-operatively, based on this definition. This finding was in line 
with our current knowledge of how breast cancer cells have the ability to cause 
hypercoagulability in patients with active malignancies. We further discovered that age, 
hypertension, cardiac history, and smoking history had no impact on coagulability. 
Therefore, the differences between patients with pathological TEG and physiological TEG 
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could be due to the stage of cancer, genetics, and a multitude of other factors. Furthermore, 
TEG is a highly sensitive test that is subject to user variability and how the blood is 
sampled. As a result, this difference could be due to improper blood sampling technique 
resulting in the presence of tissue contaminants. Interestingly, standard TEG samples for 
these patients did not display hypercoagulability. This is most likely due to the presence of 
heparin, as these samples were collected following the administration of Sub-Q heparin. 
As standard of care at BIDMC, all breast cancer patients undergoing free flap 
reconstruction received 5,000U of Sub-Q Heparin prior to surgery in pre-operative holding. 
Due to the high sensitivity of Standard TEG on residual heparin or lovenox, Heparinase 
TEGs were also performed on each blood sample in order to rule out any abnormal TEG 
values due to the presence of anticoagulants.   
The effect of heparin in whole blood sample from our patients was most easily 
visualized in pre-operative TEG samples. Differences were identifiable by all variables.  
As a result, standard TEG tracings from the same sample resulted in both reduced R, K, α-
angle, MA, and CI, and increased LY30 values, all of which are an indications of weakened 
clot formation and increased thrombolysis, due to the anticoagulant nature of heparin. 
Therefore, Heparinase TEG values were more indicative of the patient’s true hemostatic 
profile in the pre-operative setting.  
Intra-operatively, all blood samples were collected by venipuncture on a lower 
extremity at the time of anastomosis. Of the 5 patients, 4 displayed hypercoagulable TEGs 
with low R and high α-angles, but normal MA and K times when compared to normal 
limits. And of these 4 patients, only 1 additionally had a hypercoagulable TEG at baseline 
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as well. Again, this hypercoagulability was only visible in the heparinase TEG. Although 
our data is limited, based on what we know it is clear that over the course of the procedure 
patients are more likely to become hypercoagulable, when compared to their baseline 
values. Furthermore, when comparing mean R, K, and α-angle between physiological and 
pathological TEGS, they were found to be statistically significant (p = 0.04, 0.03, and 0.02, 
respectively). Whereas, MA values were not statistically significant (p =.75, respectively). 
As a result, R and α-angle values are stronger indicators of hypercoagulability in patients 
(Table 2). Furthermore, due to the time from when heparin was first administered to the 
time of anastomosis, there was a much smaller difference in TEG values between intra-
operative standard and heparinase TEGs. However, any differences in values are a direct 
result of heparin effect on whole blood. 
In addition, due to the variable nature of lower extremity trauma patients that 
present to BIDMC requiring free flap reconstruction, we were unable to recruit patients 
from this desired patient population. We know that orthopedic trauma patients generally 
present with elevated MA values, even in the presence of VTE’s, and are considered to be 
hypercoagulable (Gary et al., 2015). Based on this, we expected that those who necessitated 
free flap reconstruction to remain hypercoagulable at baseline as well. As a result, we 
expected to see hypercoagulable TEGs in this patient population as well. Furthermore, 
because most trauma patients are generally male, we were expecting breast cancer patients 
to be more hypercoagulable, since studies have shown that women are more 
hypercoagulable, when TEG values are directly compared.  
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Several limitations applied to the present study. First, no patients developed post-
operative thrombotic complications. As a result, we were not able to identify statistically 
significant predictors of thrombosis based on TEG. Second, data from such a small sample 
size is not indicative of breast cancer patients. Finally, the inability to recruit lower 
extremity trauma patients for this study left us unable to be the first to compare 
coagulability differences in there two specific populations through the use of TEG. 
To address these matters, more patients need to be recruited from both populations 
by either increasing the recruitment period or extending this study to other institutions.  
 
Conclusion 
 The ability to identify high-risk patients undergoing microvascular free tissue 
transfer could drastically reduce the risk of thrombotic complications and flap loss. TEG 
has the ability to quickly identify hypercoagulable patients and monitor changes in 
hypercoagulability over the course of the procedure. As a result, the use of TEG as a 
screening tool for patients undergoing microvascular surgery could be useful. Not only 
does it have the potential to reduce the risk of flap failure, but also allows for the early 
identification of hypercoagulable states and could allow for targeted prophylactic anti-
coagulant therapy for these patients. Future studies are needed to identify what specific 
variables cause coagulability changes over the course of the procedure, post-operative 
monitoring with TEG, and what anticoagulation regimen would be best suited for these 
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